A comprehensive view of Medicago Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
WHO will 'very likely' reject Medicago's plant-based COVID-19 vaccine because of the company's 21% ownership by cigarette manufacturer Philip Morris, WHO official says; if rejected, vaccine would be excluded from COVAX initiative for developing countries
Published:
March 16, 2022
by Forbes
|
GSK and Medicago, an affiliate of Mitsubishi Tanabe Pharma, announce Health Canada approval of the COVIFENZ COVID-19 vaccine for individuals age 18 to 64
Published:
February 24, 2022
by GlaxoSmithKline PLC
|
Medicago submits Phase 3 data supporting its COIVD-19 vaccine candidate to Health Canada for review; product will be combined with GSK's pandemic adjuvant
Published:
December 16, 2021
by Business Wire
|
Medicago and GSK announces positive Phase 3 safety and efficacy results for adjuvanted plant-based COVID-19 vaccine candidate; overall efficacy rate against all variants was 71%
Published:
December 07, 2021
by GlaxoSmithKline PLC
|
Mitsubishi Tanabe Pharma announces start of Phase 1/2 clinical study in Japan of the plant-derived virus-like particle vaccine candidate combined with GSK's adjuvant for prevention of COVID-19
Published:
September 30, 2021
by Mitsubishi Tanabe Pharma Corp.
|
Ask us about our Government & Public Policy market view
Trending Chart
Interactive chart with headline count